The pharmacological action of ulinastatin
1. The inhibitory action can effectively inhibit the activities of trypsin,
motrypsin, granulocyte elastase and cathepsin, and relieve the damage of blood
hydrolases on tissue cells;
2. Anti-inflammatory action inhibits the release of inflammatory cytokines
and lysosomal enzymes, stabilizes the cell membranes of monocytes and
neutrophils, and reduces the release of inflammatory mediators;
3. The effect of improving microcirculation and tissue perfusion inhibits
the generation of myocardial inhibitory factors, reduces the generation of
kalin, stabilizes lysosomal membrane, and improves metabolic abnormalities.
Ulinastatin, a drug derived from the human body, was made for clinical use in
Japan in 1986, and in our country in 1999. In clinical practice, new application
fields have been redeveloped, the initial anti-pancreatitis, anti-shock and
defense of surgical stimulation, and developed into the anti-inflammatory, the
protection of viscera as the specialty of urgent and critical areas of common
use of drugs.
Ulinastatin is different from the therapeutic drugs that antagonize one or
several cytokines, and it does not bring side effects like glucocorticoid, such
as immunosuppression, stress ulcer bleeding and osteoporosis. As an
anti-inflammatory supplement in vivo, ulinastatin has a positive correlation
between the severity of the disease and the dose needed to be supplemented. SIRS
is regulated by a complex signaling network, and a single drug that antagonizes
a certain cytokine is ineffective. Clinical practice has proved that when SIRS
is treated with ulinastatin in vitro, the progress of SIRS is successfully
blocked and intervened by inhibiting the excessive activation of inflammatory
reactions-related hydrolases and inflammatory cells. At present, ulinastatin is
widely used in the treatment of SAP, cardiopulmonary resuscitation, severe
multiple trauma, compound injury, burn, sepsis and shock.